about
Infection with MERS-CoV causes lethal pneumonia in the common marmosetISG15 inhibits Ebola VP40 VLP budding in an L-domain-dependent manner by blocking Nedd4 ligase activityIdentification of the promoter region of human placental 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase geneInfluenza virus A/Anhui/1/2013 (H7N9) replicates efficiently in the upper and lower respiratory tracts of cynomolgus macaques.Pathophysiology of hantavirus pulmonary syndrome in rhesus macaques.Interaction between Ebola virus glycoprotein and host toll-like receptor 4 leads to induction of proinflammatory cytokines and SOCS1.Treatment with interferon-α2b and ribavirin improves outcome in MERS-CoV-infected rhesus macaquesInnate antiviral response targets HIV-1 release by the induction of ubiquitin-like protein ISG15.Host genetic diversity enables Ebola hemorrhagic fever pathogenesis and resistance.A synthetic consensus anti-spike protein DNA vaccine induces protective immunity against Middle East respiratory syndrome coronavirus in nonhuman primates.Suppressor of Cytokine Signaling 3 Is an Inducible Host Factor That Regulates Virus Egress during Ebola Virus Infection.The broad-spectrum antiviral favipiravir protects guinea pigs from lethal Lassa virus infection post-disease onset.HIV-1 accessory proteins VPR and Vif modulate antiviral response by targeting IRF-3 for degradationMiddle East respiratory syndrome coronavirus (MERS-CoV) causes transient lower respiratory tract infection in rhesus macaquesAntiviral activity of innate immune protein ISG15.Rabies virus assembly and budding.Conserved motifs within Ebola and Marburg virus VP40 proteins are important for stability, localization, and subsequent budding of virus-like particles.Modifications of the PSAP region of the matrix protein lead to attenuation of vesicular stomatitis virus in vitro and in vivo.Prophylactic and therapeutic efficacy of mAb treatment against MERS-CoV in common marmosetsA single dose of ChAdOx1 MERS provides protective immunity in rhesus macaques
P50
Q21131359-8CC47842-B42C-4526-A54E-A9BC31A3E944Q24318462-7E66FF97-5771-4C45-9866-0DCABAE4D1F8Q28144701-0EE9375E-100E-4230-8E24-60A0086A4E75Q30365646-5B0626F2-62AD-4CA1-809B-190F5A156529Q33414924-B1B68BF8-8AE2-4C90-B9BC-9B709B3416C7Q33558670-198A0084-E957-4A79-ACA8-EA30EB4358CCQ33887877-4A2A5A83-20B9-44D5-916D-D6C3EB1EF5B5Q34335062-38C87037-BABA-439A-AA6D-7ACD6B947E35Q34445647-CEE0A103-3A0E-40A2-8980-1598EED2A6CFQ36069589-E753FEDF-0D03-4802-8BA3-F46A674DF711Q36086277-075FA634-7736-4167-8805-FECB64417FCFQ36146469-BE0AEACD-6F7B-4EEA-920D-ACDC40BA2FE9Q36559594-B874ED11-D234-47A0-8218-B9A6740063DBQ37236553-C43F9DF4-3BBE-4ACF-8BC4-BECE3072A678Q37579660-5608939F-E482-4515-B20D-2B2F5BED422CQ37877949-A8561922-0FB8-4FC2-B740-211CCD8C0926Q39759620-DF3A5F14-826E-4931-B799-F7DCE4BE89FBQ45401176-30CA93D0-8F7C-454F-A8DC-22E064C36966Q56907500-CC6664C8-F5E6-4EB2-85C1-3EB0A54BDC13Q95597746-8F781A72-E011-4D01-8E9F-DAEA91DFB4A8
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Atsushi Okumura
@ast
Atsushi Okumura
@en
Atsushi Okumura
@es
Atsushi Okumura
@nl
Atsushi Okumura
@sl
type
label
Atsushi Okumura
@ast
Atsushi Okumura
@en
Atsushi Okumura
@es
Atsushi Okumura
@nl
Atsushi Okumura
@sl
prefLabel
Atsushi Okumura
@ast
Atsushi Okumura
@en
Atsushi Okumura
@es
Atsushi Okumura
@nl
Atsushi Okumura
@sl
P108
P106
P108
P31
P496
0000-0002-7779-3059